Healthcare Services

Global Opioid-Induced Constipation Treatment Market Revenue Expected To Reach $2.54 Billion By 2030

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Forecasted Market Size Figures For The Opioid-Induced Constipation Treatment Market In 2026 And 2030?

The opioid-induced constipation treatment market has demonstrated robust growth in recent years. It is forecast to increase from $1.9 billion in 2025 to $2.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. This historical expansion can be attributed to factors such as the extensive use of opioids for chronic pain management, the limited efficacy of traditional laxatives, the rising prevalence of cancer-related pain, a scarcity of early OIC-specific therapies, and a surge in hospitalizations due to opioid side effects.

The opioid-induced constipation treatment market size is anticipated to expand significantly in the coming years. By 2030, it is projected to reach $2.54 billion, exhibiting a compound annual growth rate (CAGR) of 5.9%. This expansion during the forecast period can be ascribed to several factors, including the escalating demand for PAMORA-based treatments, a rise in long-term opioid prescriptions among older demographics, a heightened clinical emphasis on patient-centric pain management, the broader availability of online and retail pharmacies, and increased investment in the development of gastrointestinal disorder drugs. Prominent developments expected in this period encompass a greater embrace of peripherally acting μ-opioid receptor antagonists, a growing inclination towards specific OIC treatments that do not compromise pain relief, an uptick in the application of combined pharmacological and non-pharmacological interventions, an amplified effort to enhance the quality of life for individuals with chronic pain, and an improved understanding and detection of opioid-induced constipation.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

What Are The Main Drivers Accelerating The Growth Of The Opioid-Induced Constipation Treatment Market?

The increasing use of opioids for managing both cancer-related and non-cancer pain is anticipated to fuel the expansion of the opioid-induced constipation treatment market in the coming years. Cancer pain describes discomfort linked to cancer and its therapies, whereas non-cancer pain denotes discomfort arising from conditions not related to cancer. The prescription of opioids for both types of pain is motivated by the necessity for effective management of moderate to severe pain, taking into account elements like pain intensity and duration, a patient’s reaction to alternative treatments, and the broader objective of enhancing life quality while mitigating potential risks of dependency and adverse reactions. Opioid-induced constipation (OIC) treatment assists individuals experiencing cancer and non-cancer pain by alleviating constipation resulting from opioid consumption, consequently boosting general comfort, compliance with pain management plans, and quality of life without diminishing pain relief. As an illustration, data released in November 2024 by the Centers for Disease Control and Prevention, a US-based public health agency, indicated that in 2023, there was a rate of 37.5 opioid prescriptions dispensed per 100 persons. Additionally, states recording the highest opioid dispensing rates per 100 persons in 2023 comprised Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the increased use of opioids for both cancer and non-cancer pain is stimulating the expansion of the opioid-induced constipation treatment market.

How Is The Opioid-Induced Constipation Treatment Market Structured Across Different Market Segments?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting μ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

What Trends Are Shaping The Opioid-Induced Constipation Treatment Market Structure?

Major companies within the opioid use disorder (OUD) market are concentrating on developing innovative solutions, such as next-generation extended-release buprenorphine formulations. This effort aims to meet the escalating demand for long-acting, adherence-supportive treatment options that mitigate withdrawal symptoms and improve recovery outcomes. Extended-release buprenorphine formulations provide sustained medication delivery over weekly or monthly periods, offering greater convenience and stability when compared with daily oral or sublingual therapies, which might increase the risk of relapse. For instance, in May 2023, the U.S. Food and Drug Administration, a US-based federal agency, approved Brixadi (buprenorphine) extended-release injection for treating moderate to severe opioid use disorder (OUD). Brixadi is available in two dosage forms: a weekly injection for patients who commenced treatment with a single dose of a transmucosal buprenorphine product or who are presently taking the medication, and a monthly version for those already receiving the medication.

Which Industry Players Are Present In The Opioid-Induced Constipation Treatment Market?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol‑Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann‑La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Access The Complete Opioid-Induced Constipation Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Which Area Represents The Largest Portion Of The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Opioid-Induced Constipation Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Opioids Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/opioids-global-market-report

Opioid Induced Constipation Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Migraine Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795